
Pharmafocus spoke to Karen Lightning-Jones, Integrated Franchise Leader, Pipeline, to discuss the current UK climate for successfully developing drugs to …

Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting its potential to launch 20 …

Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …

Sanofi has announced plans to expand its site in Geel, Belgium, with a €300 million investment to support its pipeline …

Flexion Therapeutics has presented positive results from two pivotal clinical trials for its lead drug candidate, Zilretta, which show that …

Lilly plans to launch at least three new medicines next year, senior managers announced during a meeting with analysts and …

Janssen has outlined plans to submit ‘more than ten’ new product filings worldwide in the next four years, along with …
Merck KGaA’s pipeline has been dented by the ‘disappointing’ late-stage failure of Stimuvax in a programme with non-small cell lung …

AstraZeneca and partner Targacept will not file their depression drug TC-5214 for regulatory review. The decision comes after disappointing Phase …

Merck has showcased its most promising drug candidates, and says it expects to make eight US filings in the next …

New medicines which advance the treatment of diseases are the lifeblood of the pharmaceutical industry, and billions are invested by …